CompletedNCT03156504
Ketamine and Depression With or Without Bipolarity: A Biomarker Study
About this title
Read the official source — NCT03156504This study assessed suicidal thoughts.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study assessed suicidal thoughts.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Baltimore and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: June 1, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 75
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03156504
- Official title
Show the full official title
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Baltimore · Ann Arbor · Rochester
1 more locations
- Cincinnati
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study assessed suicidal thoughts.
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Ketamine Hydrochloride.
Who was this study for?
Listed age limits: 18 years to 65 years.
